8-K: Arbutus Biopharma Secures Moderna Settlement, Advances HBV Drug

Arbutus Biopharma reported Q2 2026 results, highlighting a $178M payment from Moderna settlement, progress on imdusiran's Phase 2b trial, and plans for a capital return to shareholders.

Summary

• Arbutus Biopharma announced its second quarter 2026 financial results and provided a corporate update.
• The company received approximately $178.4 million in July 2026 as its share of a non-contingent settlement payment from Moderna, which also included reimbursement of litigation costs.
• Arbutus expects to return up to approximately $230 million in capital to shareholders starting in Q3 2026 through share repurchases.
• The company filed three international patent enforcement lawsuits against Pfizer and BioNTech related to its lipid nanoparticle (LNP) technology.
• Arbutus achieved alignment with the FDA on the design and safety parameters for a proposed imdusiran Phase 2b clinical trial for chronic hepatitis B (cHBV).
• As of June 30, 2026, the company had $92.6 million in cash, cash equivalents, and marketable securities.
• Total revenue for the quarter was $1.0 million, a decrease from $10.7 million in the same period of 2025, primarily due to the recognition of deferred revenue in the prior year.
• Net loss for the quarter was $5.1 million, or $0.03 per share, compared to a net income of $2.5 million, or $0.01 per share, in Q2 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, driven by significant litigation settlement proceeds and progress in clinical development, outweighing the revenue decline.

Positives

• Received $178.4 million from Moderna settlement in July 2026, including litigation cost reimbursement.
• Plans to return up to approximately $230 million in capital to shareholders starting in Q3 2026.
• Achieved alignment with the FDA on the design and safety parameters for the imdusiran Phase 2b clinical trial.
• Imdusiran received Fast Track designation from the FDA in April 2026 for the treatment of chronic hepatitis B.
• Maintained a strong financial position with $92.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026.
• Research and development expenses decreased by $2.6 million compared to Q2 2025 due to cost savings and lower clinical trial costs.

Negatives

• Total revenue decreased to $1.0 million for Q2 2026 from $10.7 million in Q2 2025, mainly due to the recognition of deferred revenue in the prior year.
• Reported a net loss of $5.1 million for Q2 2026, a shift from a net income of $2.5 million in Q2 2025.
• General and administrative expenses increased due to higher stock compensation expenses.

Risks

• The company may not receive the expected dividend from Genevant on the terms or within the time expected.
• The company may determine not to proceed with a return of capital to shareholders for any reason.
• Ongoing and anticipated clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant further development.
• Arbutus may elect to change its strategy regarding its product candidates and clinical development activities.
• Arbutus may not receive the necessary regulatory approvals for the clinical development of its product candidates.
• Uncertainties associated with litigation generally and patent litigation specifically.
• Economic and market conditions may worsen.
• Market shifts may require a change in strategic focus.

Future Outlook

Arbutus expects to return capital to shareholders commencing in Q3 2026 through repurchases of up to approximately $230 million of its common shares. The company also anticipates the payment of a material dividend from Genevant in the third quarter of 2026. Arbutus intends to incorporate the FDA's feedback into a final Phase 2b protocol for imdusiran.

Management Comments

• "This has been an exciting quarter for our imdusiran development program," said Lindsay Androski, President and CEO of Arbutus.
• "In addition to obtaining Fast Track designation from the FDA on this promising drug candidate, which has achieved functional cure in 10 chronic hepatitis B patients to date, we reached alignment with the FDA on the design of our Phase 2b clinical trial."
• "I would like to publicly congratulate our research and development team for their hard work and dedication in achieving these important milestones."

Industry Context

StockSavvy.ai notes that Arbutus's progress in its cHBV program, particularly the FDA alignment on the Phase 2b trial for imdusiran and the Fast Track designation, aligns with the industry's ongoing efforts to find effective treatments for chronic hepatitis B, a significant unmet medical need. The substantial settlement from Moderna also provides a strong financial footing for continued development and potential shareholder returns, a common strategy in the biopharmaceutical sector when significant non-dilutive capital is received.

Legal Proceedings

• Filed three international patent enforcement lawsuits against Pfizer and BioNTech related to lipid nanoparticle (LNP) technology across 21 countries.
• Settlement agreement with Moderna resolved all global patent infringement litigation and patent revocation proceedings.

Related Party Transactions

• The company owns approximately 16% of the outstanding common equity of Genevant, its exclusive licensee.

Stakeholder Impact

• Shareholders: Potential return of capital up to approximately $230 million through share repurchases, and potential dividend from Genevant.
• Employees: The company has undertaken restructuring efforts, including workforce reductions, which may impact employee morale and retention.
• Creditors: The company's financial position appears stable with significant cash reserves, suggesting ability to meet obligations.

Next Steps

• Incorporate FDA feedback into a final Phase 2b protocol for imdusiran.
• Commence capital return to shareholders through share repurchases in Q3 2026.
• Anticipate payment of a material dividend from Genevant in Q3 2026.
• Continue to defend and protect intellectual property related to LNP technology through ongoing lawsuits.

Key Dates

Recommendation

The company has received significant positive news with the Moderna settlement and progress in its HBV drug development. However, the revenue decline and net loss, coupled with the inherent risks in clinical-stage biopharmaceutical development and ongoing litigation, warrant a cautious approach. The planned capital return is a positive, but the core business performance and future clinical success remain key determinants. Therefore, a 'hold' recommendation is appropriate pending further clinical data and resolution of ongoing legal matters.

Keywords

hepatitis B, imdusiran, RNAi therapeutic, lipid nanoparticle, Moderna settlement, Pfizer litigation, clinical trial, biopharmaceutical